Evidence map›Paper›PMID 31905213›Full record

ArticlePloS one2020

Efficacy of a mitochondrion-targeting agent for reducing the level of urinary protein in rats with puromycin aminonucleoside-induced minimal-change nephrotic syndrome.

Yuko Fujii, Hideki Matsumura, Satoshi Yamazaki, Akihiko Shirasu, Hyogo Nakakura, Tohru Ogihara, Akira Ashida

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Therapeutic Efficacy of Mesenchymal Stem Cells in Modulating Oxidative Stress in Puromycin-Induced Nephropathy.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yuko FujiiDepartment of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan.
Hideki MatsumuraDepartment of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan.
Satoshi YamazakiDepartment of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan.
Akihiko ShirasuDepartment of Pediatrics, Hirakata City Hospital, Hirakata, Osaka, Japan.
Hyogo NakakuraDepartment of Hemodialysis and Apheresis, Arisawa General Hospital, Hirakata, Osaka, Japan.
Tohru OgiharaDepartment of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan.
Akira AshidaDepartment of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan.ORCID 0000-0001-5972-946X
Osaka Medical and Pharmaceutical University · JPMunicipal Hirakata City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOxidative stress is a major factor responsible for minimal-change nephrotic syndrome (MCNS), which occurs most commonly in children. However, the influence of oxidative stress localized to mitochondria remains unclear. We examined the effect of a mitochondrion-targeting antioxidant, MitoTEMPO, in rats with puromycin aminonucleoside (PAN)-induced MCNS to clarify the degree to which mitochondrial oxidative stress affects MCNS. MATERIALS AND

methodsThirty Wistar rats were divided into three groups: normal saline group (n = 7), PAN group (n = 12), and PAN + MitoTEMPO group (n = 11). Rats in the PAN and PAN + MitoTEMPO groups received PAN on day 1, and those in the PAN + MitoTEMPO group received MitoTEMPO on days 0 to 9. Whole-day urine samples were collected on days 3 and 9, and samples of glomeruli and blood were taken for measurement of lipid peroxidation products. We also estimated the mitochondrial damage score in podocytes in all 3 groups using electron microscopy.

resultsUrinary protein excretion on day 9 and the levels of lipid peroxidation products in urine, glomeruli, and blood were significantly lower in the PAN + MitoTEMPO group than in the PAN group (p = 0.0019, p = 0.011, p = 0.039, p = 0.030). The mitochondrial damage score in podocytes was significantly lower in the PAN + MitoTEMPO group than in the PAN group (p <0.0001).

conclusionsThis mitochondrion-targeting agent was shown to reduce oxidative stress and mitochondrial damage in a MCNS model. A radical scavenger targeting mitochondria could be a promising drug for treatment of MCNS.

Indexed as

Drug Delivery SystemsMitochondriaNephrosis, LipoidProteinuriaAnimalsAntioxidantsLipid PeroxidationMaleOrganophosphorus CompoundsOxidative StressPiperidinesPodocytesPuromycin AminonucleosideRatsRats, WistarAntioxidantsMitoTEMPOOrganophosphorus CompoundsPiperidinesPuromycin Aminonucleoside

Identifiers

PMID31905213
PMCPMC6944386
OpenAlexW2998181547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.